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Prognostic Impact of In-Hospital and Postdischarge Heart Failure in
Patients With Acute Myocardial Infarction: A Nationwide Analysis
Using Data From the Cardiovascular Disease in Norway (CVDNOR)
Project
Gerhard Sulo, MD, PhD; Jannicke Igland, PhD; Ottar Nygard, MD, PhD; Stein Emil Vollset, MD, DrPh; Marta Ebbing, MD, PhD; Neil Poulter,
FMedSci; Grace M. Egeland, PhD; Charlotte Cerqueira, MD, PhD; Torben Jørgensen, MD, DMSci; Grethe S. Tell, MPH, PhD
Background-—Heart failure (HF) is a serious complication of acute myocardial infarction (AMI). We explored the excess mortality
associated with HF as an early or late complication of AMI and describe changes over time in such excess mortality.
Methods and Results-—All patients hospitalized with an incident AMI and without history of prior HF hospitalization were followed
up to 1 year after AMI discharge for episodes of HF. New HF episodes were classiﬁed as in-hospital HF if diagnosed during the AMI
hospitalization or postdischarge HF if diagnosed within 1 year after discharge from the incident AMI. Logistic and Cox regression
models were used to explore the excess mortality associated with HF categories. Changes over time in the excess mortality were
assessed by testing the interaction between HF status and study year. In-hospital HF increased in-hospital mortality 1.79 times
(odds ratio [OR], 1.79; 95% CI: 1.68–1.91). The excess mortality associated with HF increased by 4.3 times from 2001 to 2009
(P interaction<0.001) as a consequence of a greater decline of in-hospital mortality among AMI patients without (9% per year)
compared to those with in-hospital HF (3% per year). Postdischarge HF increased all-cause and CVD mortality 5.98 times (hazard
ratio, 5.98; 95% CI: 5.39–6.64) and 7.93 times (subhazard ratio, 7.93; 95% CI: 6.84 –9.19), respectively. The relative excess 1-year
mortality associated with HF did not change signiﬁcantly over time.
Conclusions-—Development of HF—either as an early or late complication of AMI—has a negative impact on patients’ survival.
Changes in the excess mortality associated with HF are driven by modest improvements in survival among AMI patients with HF as
compared to those without HF. ( J Am Heart Assoc. 2017;6:e005277. DOI: 10.1161/JAHA.116.005277.)
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H eart failure (HF) is a serious condition affecting38 million patients worldwide.1 Its prevalence is
expected to increase because of aging of the population
and improved survival of patients experiencing a cardiovas-
cular event.2
Acute myocardial infarction (AMI) is a frequent cause of
HF.3 The development of HF has a negative impact on the
prognosis of AMI patients4–7 and is accordingly regarded as “a
warning sign for death” among them.8
The prognostic impact of HF in patients suffering an AMI
has mainly been explored in association with short-term
mortality.5,7,9–11 A few analyses have expanded the observa-
tion period to include the AMI’s postdischarge phase.12,13
Therefore, the longer-term prognostic impact of HF is poorly
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understood. Furthermore, little is known about recent changes
over time on the short- and long-term prognostic impact of HF.
Although the overall survival of AMI patients has improved
signiﬁcantly during the last 2 decades,14–17 no survival
analyses stratiﬁed by HF status have been published. Thus,
it is not known whether the improved survival after an AMI
occur both in patients who did, and did not, develop HF.
The objective of our study was to explore the impact of HF on
in-hospital and 1-year mortality in AMI patients, with particular
focus on changes over time in such prognostic impact. To aid
our understanding of such changes, we also analyzed trends in
mortality (in-hospital and 1-year mortality) by HF status using
the nationwide cohort of patients hospitalized with an incident
AMI in Norway during 2001–2009.
Methods
Data Sources
The Cardiovascular Disease in Norway project
The Cardiovascular Disease in Norway (CVDNOR) project
(https://cvdnor.b.uib.no) contains information on CVD and
diabetes mellitus–related hospitalizations in Norway during
1994–2009. Data were retrieved from the electronic patient
administrative systems and include information on patients’
demographics, admission and discharge dates, discharge
diagnoses (up to 20), as well as all diagnostic and treatment
procedures during each hospital stay.18,19 Deaths occurring in
and outside Norway during the same period were retrieved
from the Norwegian Cause of Death Registry and linked to the
hospitalization data using the unique and permanent personal
identiﬁcation number assigned to each Norwegian resident.
Study Population, Exposure, and Outcomes
All patients aged 25 to 84 years, hospitalized with an incident
(ﬁrst) AMI20 (ICD–10 codes I21, I22) during 2001–2009 and
without prior history of HF (ICD-9 codes 402, 425.x, 428,
429.1, and 429.3 or ICD-10 codes I11.0, I13.0, I13.2, I42.x,
I43.x, and I.50.x) were included in the analyses.
The occurrence of HF during follow-up was identiﬁed using
discharge diagnosis codes (ICD-10 codes, I50.x). HF was
classiﬁed as “in-hospital HF” if diagnosed during the hospital
stay for the incident AMI and “postdischarge HF” if developed
within 1 year after discharge from the incident AMI.21
The relative excess mortality associated with HF (also
referred to here as the “prognostic impact of HF”) was
calculated as the ratio between the odds of dying among AMI
patients with HF and those without HF. The prognostic impact
of in-hospital HF was explored in connection with in-hospital
mortality. As the in-hospital mortality may be inﬂuenced by
the length of AMI hospitalization, we additionally explored the
prognostic impact of in-hospital HF on 30-day mortality.
The prognostic impact of postdischarge HF was explored in
connection with all-cause and cardiovascular (ICD-10 codes,
I00–I99) mortality within 1 year after discharge from the
incident AMI (1-year mortality). Only patients discharged alive
from the incident AMI and without in-hospital HF were
included in the latter analyses.
Comorbidities and AMI Complications
Information on relevant medical conditions such as hyperten-
sion (I10–I15), diabetes mellitus (E10–E14), renal failure
(N17–N19), chronic obstructive pulmonary disease (J40–J44,
J47), valvular heart disease (I05–I09; I34–I35), and atrial
ﬁbrillation (I48) was retrieved from any ﬁeld of discharge
diagnosis. Similarly, we identiﬁed patients in whom AMI was
complicated with pulmonary edema (J81), cardiogenic shock
(R57.0), second- (I44.1), or third- (I44.2) degree atrioventric-
ular block, ventricular ﬁbrillation (I49.0), or mechanical
complications (I23).
Data Analyses
Continuous variables are reported as means and SD and
categorical data are reported as proportions.
The prognostic impact of in-hospital HF was explored using
logistic regression and results are presented as odds ratio (OR)
and 95% CI. The prognostic impact of postdischarge HF on all-
cause mortality was explored using Cox models with HF as a
time-varying covariate and results are expressed as hazard ratio
and 95% CI. In the analyses of CVDmortality, death attributable
to other causes was treated as a competing risk event and
results are expressed as subhazard ratios (SHR) and 95% CI.
Changes over time in the excess mortality associated with
HF were explored by testing the interactions between HF
status and study year in separate analyses for in-hospital and
postdischarge HF.
Trends in the In-Hospital, 30-Day, and 1-Year
Mortality by HF Status
To better understand the factors inﬂuencing changes over
time in the excess mortality associated with HF, we analyzed
time trends in the in-hospital, 30-day, and 1-year mortality by
HF status. In these analyses, the year of AMI was the
independent variable. The estimated average annual changes
in the in-hospital, 30-day, and 1-year mortality were reported
as OR, hazard ratio, and SHR, respectively. Analyses were
adjusted for sex, age, history of prior coronary heart disease
(CHD)–related hospitalization, hypertension, diabetes
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mellitus, renal failure, obstructive pulmonary disease, valvular
heart disease, and atrial ﬁbrillation.
Trends in the Utilization of Myocardial
Revascularization During the Incident AMI
Hospitalization
We also compared rates of coronary revascularization
procedures (percutaneous coronary intervention [PCI] and
coronary artery bypass grafting) between patients with and
without HF.
Statistical analyses were performed using Stata Statistical
Software: Release 14 (Stata Corp LP, College Station, TX). The
study protocol was approved by the Regional Committee for
Medical and Health Research Ethics, Health Region West
(2015/2048).
Results
Baseline Characteristics of the Cohort
A ﬂowchart of patients’ enrollment is presented in Figure 1. A
total of 69 372 patients, of whom 68.4% were male, were
included in the study (Table 1). The mean age (SD) was 66.4
(12.3) years. A total of 11 831 patients (17.1% of the cohort)
were discharged from the AMI hospitalization with a diagnosis
of HF (in-hospital HF). Another 2566 patients (5.4% of the
population at risk) developed postdischarge HF (Table 1).
Compared to patients with postdischarge HF, patients with
in-hospital HF were younger and less often had a prior CHD-
related hospitalization (both P<0.001). Complications includ-
ing ventricular ﬁbrillation, pulmonary edema, and cardiogenic
shock were more common in patients with in-hospital
compared to those with postdischarge HF (P for all compar-
isons <0.001).
Prevalence of Comorbidities at Different Time
Periods in Patients Diagnosed With HF
The prevalence of comorbidities in patients diagnosed with in-
hospital or postdischarge HF is presented for each time
period of AMI admission in Figure 2. In patients with in-
hospital HF, the prevalence of comorbidities increased from
2001–2003 to 2007–2009; hypertension from 20.1% to
33.1%, obstructive pulmonary disease from 9.6% to 11.6%,
renal failure from 3.4% to 6.6%, valvular heart disease from
11.8% to 13.6%, and atrial ﬁbrillation from 20.0% to 21.1% (all
P for trend<0.001). The prevalence of AMI complications also
increased over the study periods: ventricular ﬁbrillation from
2.6% to 4.1% (P for trend=0.011), pulmonary edema from
Figure 1. Flowchart of patients’ enrollment and timing of development of heart failure in relation to the
incident acute myocardial infarction.
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1.1% to 2.4% (P for trend<0.001), and cardiogenic shock from
1.4% to 2.5% (P for trend=0.003). Similarly, in patients with
late-onset HF, we observed increases in the prevalence of
hypertension (from 22.4% to 41.4%; P for trend<0.001),
diabetes mellitus (from 17.1% to 21.4%; P for trend=0.023),
renal failure (from 3.8% to 5.1%; P for trend=0.015), valvular
heart disease (from 8.4% to 11.4%; P for trend=0.006), and
atrial ﬁbrillation (18.2–28.1%; P for trend<0.001). No signif-
icant changes were observed in the prevalence of AMI
complications (Figure 2).
Prognostic Impact of In-Hospital HF on Early
Mortality
In-hospital mortality
Overall, 5394 AMI patients did not survive the incident AMI
hospitalization. The 17.1% of patients who developed
in-hospital HF during 2001–2009 contributed 30.6% of
in-hospital deaths. In 2001, patients with in-hospital HF
accounted for 15.4% of all AMI cases and contributed 22.8%
of in-hospital deaths while in 2009 they accounted for
17.9% of all AMI cases and contributed 38.4% of in-hospital
deaths.
Overall, the adjusted in-hospital mortality risk in patients
with HF was 1.79 times higher than in those without HF
(OR=1.79; 95% CI: 1.68–1.91). The excess in-hospital
mortality associated with HF increased 4.3 times over the
study period (from 25% in 2001 to 133% in 2009; P for
interaction<0.001) (Figure 3 and Table S1). Although in-
hospital mortality rates were reduced in both patients with
and without HF, the decline was more pronounced among
patients without HF compared to those with HF (9% per year
[OR=0.91; 95% CI: 0.89–0.93] versus 3% per year [OR=0.97;
95% CI: 0.95–0.99], respectively) (Table 2 and Figure 4).
30-day mortality
From 2001 to 2009, the length of hospitalization for an
incident AMI was reduced signiﬁcantly (Table S2). However,
patients with HF had a longer hospitalization stay than those
without HF. To account for the potential effect of differences
in the length of AMI hospitalization on prognostic impact of
HF, we repeated the analyses using 30-day mortality as an
Table 1. Baseline Characteristics of Patients Hospitalized With an Incident AMI in Norway During 2001–2009
Patients’ Characteristics
All Patients
(n=69 372)
Patients With Heart Failure (n=14 397)
In-Hospital Heart
Failure (n=11 831)
Postdischarge Heart
Failure (n=2566) P Value*
Sex (male), n (%) 47 479 (68.4) 7480 (63.2) 1608 (62.7) 0.562
Age (y), mean (SD) 66.4 (12.3) 71.0 (11.0) 72.7 (9.9) <0.001
Age categories, n (%) <0.001
25 to 69 years 37 608 (54.2) 4365 (36.9) 747 (29.1)
70 to 84 years 31 764 (45.8) 7466 (63.1) 1819 (70.9)
Prior CHD, n (%) 8809 (12.7) 1682 (14.2) 544 (21.2) <0.001
Comorbidities, n (%)
Hypertension 20 276 (29.2) 3191 (27.0) 792 (30.9) <0.001
Diabetes mellitus 9046 (13.0) 2152 (18.2) 493 (19.2) 0.231
COPD 5019 (7.2) 1272 (10.8) 309 (12.0) 0.162
Renal failure 1651 (2.4) 577 (4.9) 118 (4.6) 0.253
Valvular heart disease 3759 (5.4) 1524 (12.9) 252 (9.8) <0.001
Atrial fibrillation 7996 (11.5) 2429 (20.5) 544 (21.2) 0.621
AMI complications, n (%)
Ventricular fibrillation 1300 (1.9) 393 (3.3) 87 (1.8) <0.001
Pulmonary edema 353 (0.5) 218 (1.8) 37 (0.7) <0.001
Cardiogenic shock 685 (1.0) 250 (2.1) 7 (0.3) <0.001
AV block (2nd/3rd degree) 933 (1.3) 231 (1.9) 42 (1.6) 0.281
Mechanical complications 675 (1.0) 230 (1.9) 20 (0.8) <0.001
AMI indicates acute myocardial infarction; AV, atrioventricular; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
*Age-adjusted comparisons of patients with in-hospital and those with postdischarge heart failure.
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alternative end point to in-hospital mortality (used in the main
analyses). The adjusted 30-day mortality risk in patients with
HF was 1.77 times higher than in those without HF (OR=1.77;
95% CI: 1.66–1.88). The excess mortality associated with HF
increased by 3 times over the study period (from 30% in 2001
to 120% in 2009; P for interaction<0.001) (Figure 3 and
Table S1). Patients with and without in-hospital HF both
experienced reductions in 30-day mortality rates over time,
but the decline was steeper among patients without HF
compared to those with (8% per year [OR=0.92; 95% CI: 0.91–
0.93] versus 3% per year [OR=0.97; 95% CI: 0.95–0.99],
respectively) (Table 2 and Figure 4).
Prognostic Impact of Postdischarge HF on 1-Year
Mortality
All-cause mortality
Overall, 2349 patients died within 1 year after discharge from
the incident AMI hospitalization. AMI patients who developed
postdischarge HF during follow-up accounted for 5.4% of AMI
cases but contributed 24.5% of all deaths (Table 3). Overall,
the adjusted 1-year mortality risk among patients with HF was
5.98 times higher than in those without HF (hazard
ratio=5.98; 95% CI: 5.39–6.64) (Figure 5 and Table S3). The
excess mortality associated with HF did not change
Figure 2. Changes over time in the prevalence of baseline comorbidities in acute myocardial infarction patients developing in-hospital and
postdischarge heart failure. CHD indicates coronary heart disease; COPD, chronic obstructive pulmonary disease; HF, heart failure.
Figure 3. Changes over time in the in-hospital and 30-day excess mortality associated with the development of in-hospital heart failure.
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signiﬁcantly over the study period (P for interaction=0.67).
One-year all-cause mortality declined among patients without
HF (5% per year [hazard ratio=0.95; 95% CI: 0.93–0.97]) but
did not change signiﬁcantly among those with HF (Table 3
and Figure 6). This was because of increases in the proportion
of non-CVD mortality among patients with HF (data not
shown).
CVD mortality
Overall, 1285 patients died because of CVD within a year
from AMI discharge. AMI patients who developed postdis-
charge HF during follow-up accounted for 5.4% of AMI cases
but contributed 29.1% of all CVD deaths (Table 3). Overall,
the adjusted 1-year CVD mortality risk among patients with
HF was 7.93 times higher (SHR=7.93; 95% CI: 6.84–9.19)
compared to those without HF (Figure 5 and Table S3). The
excess CVD mortality associated with HF did not change
signiﬁcantly over the study period (P for interaction=0.85).
Both patient groups experienced declines in 1-year CVD
mortality (Table 3). The reduction was 12% per year
(SHR=0.88; 95% CI: 0.85–0.91) in patients without HF and
7% per year (SHR=0.83; 95% CI: 0.89–0.98) in those with
HF.
Myocardial Revascularization During the Incident
AMI Hospitalization
In total, 38.6% of the study population received revascular-
ization while hospitalized for the incident AMI. The corre-
sponding proportions among patients with and without in-
hospital HF were 32.4% and 39.9%, respectively (P<0.001).
Overall, the odds of receiving myocardial revascularization
in patients with in-hospital HF were 10% lower (OR, 0.90; 95%
CI, 0.86–0.94) than in those without in-hospital HF (Table S4).
These differences narrowed over the study period (P for
interaction<0.001) because of the steeper increase in
Table 2. Time Trends in In-Hospital and 30-Day Mortality by In-Hospital Heart Failure Status
Study Year
No Heart Failure Heart Failure
AMI, Deaths, n (%) Odds Ratio* (95% CI) AMI, n Deaths, n (%) Odds Ratio* (95% CI)
In-hospital mortality
2001 6756 660 (9.8) 1reference 1232 195 (15.8) 1reference
2002 6675 574 (8.6) 0.91 (0.81–1.03) 1302 202 (15.5) 0.99 (0.80–1.23)
2003 6651 496 (7.5) 0.81 (0.71–0.92) 1426 234 (16.4) 1.10 (0.89–1.36)
2004 6270 452 (7.2) 0.79 (0.70–0.90) 1235 195 (15.8) 1.07 (0.86–1.34)
2005 6106 399 (6.5) 0.76 (0.66–0.86) 1315 186 (14.1) 1.02 (0.82–1.27)
2006 6180 332 (5.4) 0.63 (0.55–0.72) 1302 178 (13.7) 1.00 (0.80–1.25)
2007 6134 312 (5.1) 0.61 (0.53–0.70) 1296 155 (12.0) 0.89 (0.71–1.12)
2008 6395 269 (4.2) 0.51 (0.44–0.59) 1335 154 (11.5) 0.86 (0.68–1.08)
2009 6374 247 (3.9) 0.47 (0.41–0.55) 1388 154 (11.1) 0.82 (0.65–1.04)
Annual change 0.91 (0.89–0.93) 0.97 (0.95–0.99)
30-day mortality
2001 6756 708 (10.5) 1reference 1232 217 (17.6) 1reference
2002 6675 623 (9.3) 0.92 (0.82–1.04) 1302 217 (16.7) 0.96 (0.78–1.18)
2003 6651 531 (8.0) 0.80 (0.71–0.91) 1426 252 (17.7) 1.07 (0.87–1.31)
2004 6270 480 (7.7) 0.78 (0.69–0.88) 1235 219 (17.7) 1.10 (0.89–1.35)
2005 6106 442 (7.2) 0.78 (0.69–0.89) 1315 198 (15.1) 0.98 (0.79–1.22)
2006 6180 363 (5.9) 0.64 (0.56–0.73) 1302 184 (14.1) 0.93 (0.75–1.16)
2007 6134 352 (5.7) 0.64 (0.55–0.73) 1296 167 (12.9) 0.88 (0.70–1.10)
2008 6395 301 (4.7) 0.53 (0.46–0.61) 1335 162 (12.1) 0.82 (0.65–1.03)
2009 6374 279 (4.4) 0.50 (0.43–0.58) 1388 167 (12.0) 0.82 (0.64–1.02)
Annual change 0.92 (0.91–0.94) 0.97 (0.94–0.99)
AMI indicates acute myocardial infarction.
*Analyses adjusted for sex, age, previous coronary heart disease, hypertension, diabetes mellitus, renal failure, chronic obstructive pulmonary disease, valvular heart disease, and atrial
ﬁbrillation.
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myocardial revascularization rates among patients with versus
without HF (26% per year [OR=1.26; 95% CI: 1.23–1.28]
versus 17% per year [OR=1.17; 95% CI: 1.16–1.19]).
Discussion
Our study demonstrates that development of HF has a
substantial negative impact on survival among AMI patients.
Such negative impact is strongly inﬂuenced by timing of HF
occurrence in relation to AMI. In-hospital HF nearly doubled
the risk of dying at the hospital. Moreover, the excess
mortality associated with this HF category increased signif-
icantly over the study period, because of more modest
improvement in survival among AMI patients with, versus
those without HF. Postdischarge HF increased the risk of 1-
year all-cause and CVD mortality by nearly 6 and 8 times,
respectively, and its excess mortality remained stable over the
study period.
A few studies have focused on the short-term prognostic
impact of HF among CHD patients. In a register-based study
enrolling 4825 patients with non-ST-elevation MI in Canada
during 1999–2003, the presence of HF on admission
increased the odds of in-hospital mortality by 1.87 times.6
Similarly, HF on admission increased the odds of in-hospital
mortality by 2.2 times among 13 707 patients enrolled in the
Global Registry of Acute Coronary Events (GRACE) registry
from 1999 to 2001.11 In a pooled analysis of 7 randomized
clinical trials including 46 519 non-ST-elevation myocardial
infarction patients during 1994–2008, the presence of HF on
admission or developing during the AMI hospitalization
increased 30-day mortality by 1.74 and 2.34 times, respec-
tively, compared to patients without HF.22
Lewis et al23 assessed the prognostic impact of postdis-
charge HF in a cohort of 10 040 stable AMI survivors included
in the Valsartan in Acute Myocardial Infarction (VALIANT)
study. They reported an 8 times increase in the risk of dying
during a median follow-up of 25 months among patients with
HF compared to those without HF. Another study included
25 324 patients with acute coronary syndrome in Canada
between 2002 and 2008 and found that postdischarge HF
increased 1-year mortality by 4.6 times.12
Results from our study extend previous knowledge on the
negative impact of HF in prognosis of patients suffering an
acute coronary event. To the best of our knowledge, it is the
ﬁrst analysis exploring simultaneously the role of HF devel-
oping while at the hospital or following AMI discharge on
mortality, focusing on changes over time in the prognostic
impact of HF.
The observed changes in the prognostic impact of HF
should be interpreted in the context of the changes charac-
terizing AMI clinical expression and survival. Although in-
hospital (and 30-day) mortality following an AMI has improved
Figure 4. Time trends of in-hospital and 30-day mortality by in-hospital heart failure status.
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overall, the proportion of AMI cases discharged with a
diagnosis of HF increased by 20% during 2001–2009 (Sulo G
et al, Unpublished data). This suggests that a higher propor-
tion of patients are presenting with a more severe form of
AMI, supported by the observed increase in the proportion of
ventricular ﬁbrillation, pulmonary edema, and cardiogenic
shock as well as accompanying comorbidities. We have
previously reported a decline of 47% in incident out-of-hospital
coronary death rates during 2001–2009.20 Taken together,
these ﬁndings indicate that the increasing proportion of
severely ill patients reaching the hospital alive contribute to
the increased burden of HF as an early complication of AMI.
Changes in the excess mortality associated with in-hospital
HF are explained by differences in the magnitude of reduc-
tions characterizing in-hospital mortality between patients
with and without HF; in-hospital mortality in patients with HF
declined modestly while among those without HF the decline
was more pronounced. These different trends are likely to be
inﬂuenced by differences in the trends of AMI severity
between patients with and without HF. Indeed, we observed
an increase in the prevalence of ventricular ﬁbrillation,
pulmonary edema, and cardiogenic shock (all reliable indica-
tors of AMI severity) among patients with in-hospital HF, while
no changes in the prevalence of these indicators were
observed among patients without HF.
Interestingly, the excess mortality associated with in-
hospital HF increased over time while gaps in the utilization of
myocardial revascularization procedures between patients
with and without HF procedures narrowed. Because of the
observational nature of our study and lack of information on
whether the myocardial revascularization preceded or came
after the development of HF, we could not account for the role
of revascularization in the analyses. However, it appears that
the excess mortality associated with HF is also inﬂuenced by
factors other than myocardial revascularization, including
differences in the use and efﬁcacy of cardiac drugs between
patients with and without HF.24
Although postdischarge HF accounts for only 20% to 25%
of AMI-related HF, the excess mortality it conveys greatly
exceeded that of in-hospital HF. Thus, postdischarge HF is an
Table 3. Time Trends in 1-Year Mortality by Postdischarge Heart Failure Status
Study Year
No Heart Failure Heart Failure
AMI, n
Deaths,
n (%)
Hazard Ratio*,
(95% CI) AMI, n
Deaths,
n (%)
Hazard Ratio*
(95% CI)
All-cause mortality
2001 5681 272 (4.8) 1reference 415 99 (23.9) 1reference
2002 5726 257 (4.5) 0.93 (0.79–1.11) 375 77 (20.5) 0.89 (0.66–1.19)
2003 5821 258 (4.4) 0.93 (0.78–1.10) 334 73 (21.9) 0.87 (0.64–1.17)
2004 5502 202 (3.7) 0.77 (0.64–0.92) 316 67 (21.2) 0.86 (0.63–1.16)
2005 5412 186 (3.4) 0.75 (0.62–0.90) 295 75 (25.4) 1.07 (0.79–1.45)
2006 5551 202 (3.6) 0.80 (0.67–0.96) 297 66 (22.2) 0.92 (0.67–1.26)
2007 5563 190 (3.4) 0.74 (0.61–0.89) 259 56 (21.6) 0.98 (0.70–1.37)
2008 5851 206 (3.5) 0.77 (0.64–0.93) 275 63 (22.9) 0.99 (0.72–1.38)
Annual change 0.95 (0.93–0.97) 1.01 (0.97–1.05)
Cardiovascular mortality
2001 5681 179 (3.2) 1reference 415 77 (18.6) 1reference
2002 5726 158 (2.8) 0.86 (0.69–1.06) 375 53 (14.1) 0.78 (0.55–1.10)
2003 5821 136 (2.3) 0.73 (0.59–0.92) 334 51 (15.3) 0.77 (0.55–1.09)
2004 5502 101 (1.8) 0.57 (0.45–0.73) 316 45 (14.2) 0.74 (0.51–1.08)
2005 5412 81 (1.5) 0.49 (0.37–0.64) 295 53 (18.0) 0.96 (0.67–1.37)
2006 5551 95 (1.7) 0.55 (0.43–0.71) 297 37 (12.5) 0.64 (0.44–0.95)
2007 5563 83 (1.5) 0.47 (0.36–0.61) 259 34 (13.1) 0.70 (0.48–1.08)
2008 5851 78 (1.3) 0.42 (0.32–0.55) 275 24 (8.7) 0.46 (0.29–0.74)
Annual change 0.88 (0.85–0.91) 0.93 (0.89–0.98)
AMI indicates acute myocardial infarction.
*Analyses adjusted for sex, age, previous coronary heart disease, hypertension, diabetes mellitus, renal failure, chronic obstructive pulmonary disease, valvular heart disease, and atrial
ﬁbrillation.
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important source of mortality. The excess mortality associ-
ated with postdischarge HF was more evident in relation to
CVD than to all-cause mortality. This is to be expected, as
non-CVD deaths involve other pathophysiological mecha-
nisms, not directly inﬂuenced by HF.
Our results suggest that HF may, in the future, slow the
rate of reductions characterizing CVD mortality, should
the observed trends in the prognostic impact of HF continue.
The modest improvements in short-term survival among
patients with HF are offset by increased HF incidence rates.
Therefore, reducing the occurrence of HF by addressing
coronary risk factors in the general population and shortening
the time from onset of symptoms to receiving specialized care
becomes of paramount importance in reducing CVD mortality.
Strength and Limitations
Our study is one of few analyses exploring simultaneously the
prognostic impact of in-hospital and postdischarge HF, with
additional focus on changes over time characterizing this
prognostic impact. The use of a nationwide cohort, without
age, sex, or geographical restriction increases the
Figure 6. Time trends of 1-year mortality by postdischarge heart failure status.
Figure 5. Changes over time in the 1-year excess mortality associated with the development of postdischarge heart failure.
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generalizability of our ﬁndings. Moreover, troponin measure-
ment was already included in the AMI diagnostic algorithm in
Norway by 2001.25 Hence, the inclusion procedures of
patients in the cohort were fairly consistent over the study
period. We were also able to exclude previous episodes of AMI
and HF using a retrospective search of 7 years.26
Our study has some potential limitations. Data were
obtained from electronic patient administrative systems and
do not include information on lifestyle indicators such as
smoking, physical activity, obesity, or alcohol drinking
patterns. Furthermore, we were unable to correctly classify
all AMIs into ST-elevation myocardial infarction and non-ST-
elevation myocardial infarction based on ICD-10 codes.
Therefore, we did not conduct separate analyses for each
AMI type. However, previous studies have demonstrated that
the magnitude27–29 and prognostic impact11 of HF as a
complication of the 2 AMI types are similar.
The CVDNOR database does not have information on HF
severity or left ventricular ejection fraction. Therefore, we
were unable to stratify analyses by HF severity. Although HF
with preserved ejection fraction is thought to prevail in the
community, its prognosis was found to be similar to that of HF
with reduced ejection fraction.30
Patients presenting with HF on admission could not be
distinguished from those developing HF during the AMI
hospitalization; however, it has been reported that both
components of early-onset HF carry a similar risk on 30-day
mortality.22
We also lacked information on prescription of and adher-
ence to medication upon hospital discharge and participation
in rehabilitation programs. Hence, we could not assess the
additional contribution of secondary prevention in the excess
mortality associated with late-onset HF.
Our results should be interpreted with caution and conclu-
sions drawn considering the abovementioned limitations.
Conclusion
In-hospital HF was associated with increased early mortality in
patients hospitalized with an incident AMI. The in-hospital and
30-day survival gap between AMI groups increased over time
because of slower declines in mortality rates among patients
with, compared to those without in-hospital HF. Postdischarge
HF substantially increased 1-year mortality following AMI
discharge, although the excessive mortality associated with this
HF category did not change signiﬁcantly over the study period.
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Table S1. Changes over time in the excess mortality associated with in-hospital HF (Heart Failure) 
Study  
year 
 Odds ratio 
(95% CI) 
P  
for interaction* 
    
In-hospital mortality    
  2001  1.25 (1.04–1.50)  
 2002  1.41 (1.17–1.69)  
 2003  1.80 (1.58–2.25)  
 2004  1.77 (1.46–2.15)  
 2005  1.79 (1.47–2.17)  
 2006  2.17 (1.77–2.67)  
 2007  2.04 (1.65–2.53)  
 2008  2.32 (1.87–2.88)  
 2009  2.33 (1.85–2.89)  
Overall (2001–2009)  1.79 (1.68–1.91) <0.001 
30-day mortality    
  2001  1.30 (1.09–1.55)  
  2002  1.40 (1.17–1.67)  
  2003  1.89 (1.59–2.25)  
  2004  1.95 (1.62–2.34)  
  2005  1.70 (1.41–2.05)  
  2006  2.02 (1.66–2.47)  
  2007  1.95 (1.58–2.40)  
  2008  2.17 (1.75–2.68)  
  2009  2.20 (1.78–2.73)  
 Overall (2001–2009)  1.77 (1.66–1.88) <0.001 
Analyses adjusted for sex, age, previous coronary heart disease, hypertension, diabetes 
mellitus, chronic obstructive pulmonary disease, valvular heart disease, renal failure and atrial 
fibrillation. 
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Table S2. Length of hospitalization for the incident acute myocardial infarction 
Study year  Length of hospitalization (days), median (IQR) 
     
  No in-hospital heart failure  In-hospital heart failure 
         
  All 
patients 
(n=57 541) 
 Discharged 
alive 
(n=53 800) 
 All 
patients 
(n=11 831) 
 Discharged 
alive 
(n=10 178) 
         
Overall 
(2001-2009) 
 5 (4–8)  6 (4–8)  8 (5–15)  9 (6–15) 
2001  6 (5–9)  6 (5–9)  9 (6–14)  9 (7–15) 
2002  6 (5–9)  6 (5–9)  9 (6–15)  9 (6–15) 
2003  6 (4–9)  6 (5–9)  9 (6–15)  9 (6–15) 
2004  6 (4–8)  6 (4–8)  9 (6–15)  9 (6–16) 
2005  5 (4–8)  5 (4–8)  9 (5–16)  9 (6–17) 
2006  5 (4–8)  5 (4–8)  9 (5–16)  9 (6–16) 
2007  5 (4–7)  5 (4–7)  8 (5–15)  9 (6–15) 
2008  5 (4–7)  5 (5–7)  8 (5–15)  8 (5–15) 
2009  5 (3–7)  5 (4–7)  7 (5–13)  8 (5–14) 
P for trend  <0.001  <0.001  0.001  0.002 
IQR indicates interquartile range. 
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Table S3. Changes over time in the excess one-year mortality associated with post-discharge heart failure  
 
Study year  All-cause mortality  Cardiovascular mortality 
       
  Hazard ratio 
(95% CI) 
P  
for interaction 
 Subhazard ratio  
(95% CI) 
P  
for interaction  
  
 
 
  
 2001  6.58 (5.13–8.45)   8.15 (5.36–11.34)  
 2002  5.73 (4.35–7.54)   7.15 (4.95–10.33)  
 2003  4.39 (3.29–5.87)   5.77 (3.91–8.53)  
 2004  7.22 (5.34–9.77)   11.22 (7.32–17.20)  
 2005  6.87 (5.00–9.43)   14.50 (9.20–22.85)  
 2006  5.35 (3.90–7.33)   5.90 (3.64–9.57)  
 2007  6.67 (4.79–9.30)   9.60 (5.85–15.73)  
 2008  6.44 (4.70–8.82)   6.99 (4.04–12.06)  
Overall (2001–2008)  5.98 (5.39–6.64) 0.67  7.93 (6.84–9.19) 0.85 
Analyses adjusted for sex, age, previous coronary heart disease, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, valvular heart disease, 
renal failure and atrial fibrillation. 
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Table S4. Changes over time in the odds of receiving myocardial revascularization between patients with 
and without early-onset heart failure: a CVDNOR project  
Study 
year 
 Odds ratio  
(95% CI) 
P  
for interaction 
  
  
 2001  0.74 (0.61–0.90)  
 2002  0.72 (0.60–0.85)  
 2003  0.69 (0.59–0.80)  
 2004  0.75 (0.65–0.87)  
 2005  0.77 (0.68–0.88)  
 2006  0.87 (0.76–0.98)  
 2007  0.99 (0.88–1.13)  
 2008  1.09 (0.96–1.23)  
 2009  1.14 (1.01–1.29)  
Overall (2001–2009)  0.90 (0.86–0.94) <0.001 
Analyses adjusted for sex, age, previous coronary heart disease, hypertension, diabetes, renal failure, 
chronic obstructive pulmonary disease, valvular heart disease and atrial fibrillation. 
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